Oncolytics Biotech Inc announces that a poster by Dr. Maureen E. Lane et al. of Cornell University, entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts" is scheduled to be presented today at the American Association for Cancer Research Annual Meeting in Los Angeles, CA. The researchers found that treatment of human colon cancer cell lines with the combination of REOLYSIN® and gemcitabine resulted in both in vitro and in vivo synergy.

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.

A compound found in blueberries shows promise of preventing colon cancer in animals, according to a joint study by scientists at Rutgers University and the U.S. Department of Agriculture.

An analysis of 17 studies from nine countries has found that the more lymph nodes that are removed and examined during surgical treatment of colon cancer, the better the outcome appears to be for patients.

The number of lymph nodes removed and examined for tumor cells appears to be associated with the likelihood of survival after surgery in colon cancer patients, according to a study in the March 21 Journal of the National Cancer Institute. Health care providers should consider the number of lymph nodes that were removed and evaluated when examining the quality of care that colon cancer patients receive, according to the paper's authors.

A straightforward strategy from computer analysis to experimental validation in a colon cancer model

NYC subway hero Wesley Autrey Joins effort to save more lives by urging New Yorkers to get checked for colon cancer.